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The EXCITE Trial
A Major Step Forward for Restorative Therapies in Stroke
Steven C. Cramer, MD
Much of the attention in the field of stroke is focused onprevention, emergency response, and management of
the acute inpatient stay. Despite these efforts, many patients
are left with substantial disability. Patients survive their
stroke for a mean of 8 years, making poststroke disability a
highly prevalent condition; most of the days during which
stroke affects the life of the patient occur in this chronic
disability phase.
Increased attention is being paid to an emerging set of
therapeutic targets that are related to repair and restoration.
Such restorative therapies focus on improving function in
surviving brain areas rather than salvaging acutely threatened
tissue and therefore might be available to a high proportion of
patients with stroke. Animal studies have suggested a wide
range of potential restorative therapies, including interven-
tions based on physical, cellular, pharmacological, and elec-
tromagnetic approaches. However, to date, there has been
limited translation of these preclinical findings into late-phase
human clinical trials. In this regard, the Extremity Constraint
Induced Therapy Evaluation (EXCITE) trial1 is a major step
forward. It is unique among trials of restorative interventions
for its size, meticulous multisite organization, preparation,2
duration of follow up, derivation from biological principle,
and application of clinical trial methodology. In many ways,
the EXCITE trial represents a paradigmatic shift in restor-
ative stroke trials.
The EXCITE trial was a prospective, single-blind, random-
ized, multisite clinical study conducted at 7 US academic
institutions between 2001 and 2003. The study randomized a
total of 222 patients with a first ischemic or hemorrhagic
stroke. The index event had to be in the previous 3 to 9
months, a time period during which spontaneous recovery has
generally reached a plateau and before many chronic post-
stroke changes such as atrophy or spasticity are maximally
severe. Participants had moderate, but not severe, deficits.
For example, each needed to be able to actively move the
wrist through at least 10° range of motion, demonstrate good
balance, and have no advanced cognitive impairment. Those
already showing substantial use of the affected arm were
excluded.
Enrollees were randomized to either customary care or
constraint-induced therapy. Constraint-induced therapy con-
sisted of 2 main components applied in parallel over a 2-week
period: subjects performed intense practice of functional
tasks using the affected hand for 6 hours per day plus subjects
reduced use of the unaffected hand by covering it with a mitt
for at least 90% of waking hours. This therapy is based on
Taub’s observations3 in deafferented monkeys that disability
can arise in part from learned nonuse of an impaired arm.
The trial found significantly positive results for both of the
prespecified2 primary end points, which were measured 1
year after study enrollment and thus 50 weeks after comple-
tion of therapy. The Wolf Motor Function Test, an objective,
valid, reliable measure of distal and proximal arm motor
function, showed a 52% reduction in time to complete its
tasks, significantly (P0.001) better than the 26% reduction
found in those in the customary care group. The Motor
Activity Log, a subjective, valid, reliable scale that records
estimates of affected arm use, showed a 76% increase in
quantity and a 77% increase in quality of arm use, each
significantly (P0.001) better than the 43% and 41% respec-
tive increases found in the customary care group. Of note,
treatment effects did not differ according to a 2-level strati-
fication of baseline arm motor function.
The authors of the EXCITE study are to be congratulated
on many levels. The clinical follow-up period of 1 year is
remarkable for any stroke trial as was the retention rate of
76% out to this time point. Behavioral data were collected
from the good arm as an internal control; indeed, this showed
no differences between treatment groups over time and
further increased confidence in results reported for the af-
fected arm. The use of adaptive randomization helped achieve
good balance between treatment groups in baseline measures,
an issue that has plagued some prior restorative clinical trials.
The authors carefully and thoroughly tackled thorny issues
that are central to trials that intervene in the chronic phase and
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likely of some relevance to stroke trials that intervene in the
acute phase but have assessments in the chronic phase. Such
issues include assessment of behavioral compliance and
measurement of rehabilitation therapies not prescribed as part
of the study protocol.
The study also raises a number of important questions. The
fraction of patients with stroke for whom these results hold
promise remains to be determined. The requirement that a
patient demonstrate 10° of active wrist extension is used to
increase the likelihood that the affected arm will improve
after therapy, but this also excludes a large fraction of the
stroke population. Estimates vary, but only 6.3% of patients
screened in this trial and 18% of those screened in a separate
study4 were ultimately found to be eligible to receive
constraint-induced therapy. A more theoretical estimate is
that 20% to 25% of patients with stroke might be eligible.5
The exact component(s) of constraint-induced therapy
critical to the observed clinical gains requires further clarifi-
cation as noted by the authors. Thus, the contribution of
intense practice by the affected limb needs to be disentangled
from the contribution of constraining the good limb. Note that
historically, however, such uncertainty has not prevented
implementation of therapy in the setting of vascular disease.
For example, the extent to which aspirin’s preventative
effects are attributable to antiplatelet versus antiinflammatory
activities remains to be fully clarified, yet this therapy is
widely prescribed to patients with stroke.6 Interpretation of
the EXCITE trial is also complicated by the fact that the
active and the control groups varied by both the amount and
the nature of therapy. This leaves open the question as to how
much of the observed benefit in the constraint-induced
therapy group was attributable to simply receiving more
hours of intervention than that provided to subjects in the
customary care group. Also, the neurobiological mechanism
of treatment effect remains unclear. For example, studies
suggest a key role by the contralesional hemisphere among
weaker patients7 and by the ipsilesional hemisphere among
stronger patients.8 Further studies of treatment mechanism
might provide insights useful to broader clinical application
of this therapy.
A minor feature of the EXCITE study design is noteworthy
and could be important to future restorative trials; those
randomized to the usual care arm were offered constraint-
induced therapy after the 12-month assessments were com-
pleted. These were patients who had measurable disability
after stroke, eagerly signed up to be part of a research study,
and were then given no active intervention. My experience in
restorative trials initiated in the chronic phase of stroke is that
recruiting subjects represents a major challenge. This feature
of the study design is therefore likely important to addressing
the challenging issue of subject recruitment in this setting.
One potential future direction for constraint-induced ther-
apy is to identify subjects most likely to derive benefit by
using entry criteria that go beyond the clinical examination
methods used in the EXCITE trial. The biological target of
this therapy is nervous system function. Several studies
suggest that a more direct assessment of brain injury and
brain function can improve prediction of response to post-
stroke therapy.9–14 When the goal is to improve behavioral
outcome by boosting brain function, a baseline measure of
brain function might provide useful insights not available
from the bedside examination.
The EXCITE trial suggests that multicenter, randomized,
controlled phase III studies of restorative therapies can be
successfully completed in the chronic phase after stroke. The
last decade has seen major advances in the science of human
brain repair.15 The EXCITE trial represents a major step
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